Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Wolfe Research Downgrades Adient to Peer Perform

Wolfe Research Downgrades Adient to Peer Perform

Wolfe Research analyst Rod Lache downgrades Adient (NYSE:ADNT) from Outperform to Peer Perform.

byBenzinga Newsdesk

February 9, 2023

1 minute read

Wolfe Research analyst Rod Lache downgrades Adient (NYSE:ADNT) from Outperform to Peer Perform.

Analyst Ratings

Beyond The Numbers: 6 Analysts Discuss Catalent Stock

By Benzinga Insights

April 4, 11:01 AM

In the preceding three months, 6 analysts have released ratings for Catalent (NYSE:CTLT), presenting a wide array of…

CTLT

Analyst Ratings

Analyst Ratings for Restaurant Brands Intl

By Benzinga Insights

September 20, 9:01 AM

Restaurant Brands Intl (NYSE:QSR) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent…

QSR

EXCLUSIVE: NY Cannabis Market Optimism Prevails Despite ‘Absurd’ Taxes, Illegal Operators, Lawsuits

By Nina Zdinjak

September 28, 4:58 PM

Ever since the launch of the legal cannabis market in New York last year, the industry has been dealing with one setback after another.

ACRHF

Cutera, Inc. Announces Preliminary Unaudited Financial Results For FY22; Expects To Report Revenue In The Range Of $252M-$253M For FY22 Vs Prior Guidance Of $255M-$260M

By Benzinga Newsdesk

January 9, 9:54 AM

Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced certain preliminary, unaudited financial results for the year ended

CUTR

Wolfe Research Downgrades Adient to Peer Perform

Related Posts

Beyond The Numbers: 6 Analysts Discuss Catalent Stock

Analyst Ratings for Restaurant Brands Intl

EXCLUSIVE: NY Cannabis Market Optimism Prevails Despite ‘Absurd’ Taxes, Illegal Operators, Lawsuits

Cutera, Inc. Announces Preliminary Unaudited Financial Results For FY22; Expects To Report Revenue In The Range Of $252M-$253M For FY22 Vs Prior Guidance Of $255M-$260M